CAJ | 학술논문

目的：探讨水飞蓟宾联合软肝丸治疗血吸虫病肝纤维化的疗效、机制及安全性。方法将200例血吸虫病肝纤维化患者随机分为对照组和治疗组，每组100例，分别采用水飞蓟宾（对照组）、水飞蓟宾联合软肝丸口服（治疗组），于治疗3、6、9个月和12个月，比较观察2组患者的临床效果。结果治疗12个月后，患者5项临床症状治疗组明显减轻，总有效率均达75%以上，均显著高于对照组。肝脏B超分级治疗组与对照组比较，3、6个月时无改善（P均＞0.05），9、12个月时，治疗组好于对照组（P均＜0.05）。治疗组治疗3、6个月时均无改善（P均＞0.05），9、12个月时较6个月时有改善（P均＜0.05）。血清肝纤维化四项，治疗3个月时，治疗组与对照组差异无统计学意义（P＞0.05）；6、9、12个月时，差异均有统计学意义（P均＜0.05）；治疗组治疗3、6个月时比较，差异无统计学意义（P＞0.05），9、12个月时均低于6个月时（P均＜0.05）。治疗过程中未出现明显不良反应。结论水飞蓟宾联合软肝丸有较好的抗血吸虫病肝纤维化的作用。
목적：탐토수비계빈연합연간환치료혈흡충병간섬유화적료효、궤제급안전성。방법장200례혈흡충병간섬유화환자수궤분위대조조화치료조，매조100례，분별채용수비계빈（대조조）、수비계빈연합연간환구복（치료조），우치료3、6、9개월화12개월，비교관찰2조환자적림상효과。결과치료12개월후，환자5항림상증상치료조명현감경，총유효솔균체75%이상，균현저고우대조조。간장B초분급치료조여대조조비교，3、6개월시무개선（P균＞0.05），9、12개월시，치료조호우대조조（P균＜0.05）。치료조치료3、6개월시균무개선（P균＞0.05），9、12개월시교6개월시유개선（P균＜0.05）。혈청간섬유화사항，치료3개월시，치료조여대조조차이무통계학의의（P＞0.05）；6、9、12개월시，차이균유통계학의의（P균＜0.05）；치료조치료3、6개월시비교，차이무통계학의의（P＞0.05），9、12개월시균저우6개월시（P균＜0.05）。치료과정중미출현명현불량반응。결론수비계빈연합연간환유교호적항혈흡충병간섬유화적작용。
Objective To explore the efficacy,mechanism and safety of silibinin combined with Ruangan pills(a Chinese herbal preparation)in the treatment of schistosomiasis liver fibrosis. Methods A total of 200 patients with schistosomiasis liver fibrosis were randomly divided into a control group and a treatment group,and 100 patients in each group were respectively admin-istered with oral silibinin alone and oral silibinin combined with Ruangan pills,respectively. The curative effects in the two groups were evaluated in 3 months,6 months,9 months and 12 months respectively. Results The common five clinical symptoms of schistosomiasis liver fibrosis patients significantly relieved in the treatment group 12 months after the therapy,and the total effi-ciency reached more than 75%,which were significantly higher than that in the control group. In the treatment group and the con-trol group,there was no improvement in the liver B ultrasonic classification 3 months and 6 months after the therapy(P>0.05);however,in 9 months and 12 months,the liver B ultrasonic classification in the treatment group was better than that in the control group(P<0.05,P<0.01,respectively). For the four serum indexes of liver fibrosis,there was no significant differences between the two groups in 3 months,however,in 6 months,9 months,and 12 months,there was a significant improvement in the treat-ment group compared with the control group. There were no obviously adverse effects in two groups. Conclusion Silibinin com-bined with Ruangan pills has a better curative effect in the treatment of schistosomiasis liver fibrosis.